All Updates

All Updates

icon
Filter
Partnerships
Foundation Medicine partners with Merck to develop companion diagnostics
Precision Medicine
Jun 5, 2023
This week:
Product updates
Hexagon unveils Advanced Compensation for metal 3D printing
Additive Manufacturing
Yesterday
Funding
Eden AI raises EUR 3 million in seed funding to accelerate product development
Generative AI Infrastructure
Nov 21, 2024
M&A
Wiz acquires Dazz to expand cloud security remediation capabilities
Next-gen Cybersecurity
Nov 21, 2024
Partnerships
Immutable partners with Altura to enhance Web3 game development and marketplace solutions
Web3 Ecosystem
Nov 21, 2024
Funding
OneCell Diagnostics raises USD 16 million in Series A funding to enhance cancer diagnostics
Precision Medicine
Nov 21, 2024
Partnerships
BioLineRx and Ayrmid partner to license and commercialize APHEXDA across multiple indications
Precision Medicine
Nov 21, 2024
Product updates
SOPHiA GENETICS announces global launch of MSK-IMPACT powered with SOPHiA DDM
Precision Medicine
Nov 21, 2024
Product updates
Biofidelity launches Aspyre Clinical Test for lung cancer detection
Precision Medicine
Nov 21, 2024
Partnerships
Spendesk partners with Adyen to enhance SMB spend management with banking-as-a-service solution
Business Expense Management
Nov 21, 2024
M&A
Mews acquires Swedish RMS provider Atomize to enhance Hospitality Cloud platform
Travel Tech
Nov 21, 2024
Precision Medicine

Precision Medicine

Jun 5, 2023

Foundation Medicine partners with Merck to develop companion diagnostics

Partnerships

  • Companion diagnostics developer Foundation Medicine has entered a strategic collaboration with multinational pharmaceutical company Merck KGaA, Germany, to develop companion diagnostics using FoundationOne CDx and FoundationOne Liquid CDx for selected cancer treatments in the US market. This is an extension of their previous partnership focused on data solutions, which was established in 2020.

  • The partnership aims to leverage Foundation Medicine's comprehensive genomic profiling tests to identify patients with genomic alterations that may benefit from specific targeted therapies. The collaboration will support the development of personalized treatment options for cancer patients by using molecular profiling to guide treatment decisions and optimize therapy development. This will enable oncologists to use FoundationOne CDx and FoundationOne Liquid CDx as companion diagnostics to identify eligible patients for targeted therapies.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.